OMEC.AI

Predicting Drug Success in Clinical Trials

Health Tech & Life Sciences
Non Active, Jul 2023 ceased to operate

Company Overview

Snapshot

Founded in September 2022 by Ori Shachar and Amir Harel, OMEC.AI secured $2 million in seed funding across one round from two investors. The company ceased operations in July 2023.

Business overview

OMEC.AI is a Health Tech & Life Sciences company focused on improving the success rates of clinical trials within the pharmaceutical industry. The company develops an automated, data-driven solution that assesses the clinical trial-readiness of proposed drugs, aiming to enable pharmaceutical companies to make more informed decisions during the pre-clinical process. Its core technology leverages artificial intelligence to serve the Drugs Discovery & Development sector, targeting laboratories and pharmaceutical companies.

Strategic signal

OMEC.AI ceased operations in July 2023, less than a year after its founding. This indicates a rapid conclusion to its venture, signaling to investors a significant challenge in its business model or market viability despite initial funding and support from prominent pharmaceutical and tech entities.

Company Intelligence Q&A

What is OMEC.AI's primary mission?
OMEC.AI's mission is to assist pharmaceutical companies in increasing their success rates in clinical trials by facilitating data-driven decisions during the pre-clinical development phase.
When was OMEC.AI founded and by whom?
OMEC.AI was founded in September 2022 by co-founders Ori Shachar and Amir Harel.
What was the total funding raised by OMEC.AI?
OMEC.AI raised $2 million in seed funding in September 2022 from AION Labs and Israel Innovation Authority.
Which investors participated in OMEC.AI's funding round?
In September 2022, OMEC.AI received seed funding from AION Labs and Israel Innovation Authority.
What is the current operational status of OMEC.AI?
OMEC.AI ceased to operate in July 2023.